報價延遲最少15分鐘:2025/09/03 18:55 EDT
盤後時段
|
||||
|
7.85 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.85
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.12/0.47
|
|
企業價值
2.86B
|
| 資產負債 |
|
每股賬面淨值
0.66
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
528.30M
|
|
每股收益
1.21
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/03 18:55 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants;a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
